[Glycopeptide-induced cutaneous adverse reaction].
Nosbaum
A
A
Rozières
A
A
Ben Said
B
B
Nicolas
J-F
JF
Bérard
F
F
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology*; D004802:Eosinophilia / Q000139:chemically induced; D005189:False Positive Reactions; D006020:Glycopeptides / Q000009:adverse effects*; D015654:Herpesvirus 6, Human / Q000187:drug effects / Q000502:physiology; D006801:Humans; D010630:Phenindione / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D012882:Skin Tests / Q000009:adverse effects / Q000379:methods; D017334:Teicoplanin / Q000009:adverse effects / Q000494:pharmacology; D014640:Vancomycin / Q000009:adverse effects / Q000494:pharmacology; D014775:Virus Activation / Q000187:drug effects
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D010630:Phenindione; D017334:Teicoplanin; D014640:Vancomycin; C017673:fluindione